A case of transient existence of SARS-CoV-2 RNA in the respiratory tract with the absence of anti-SARS-CoV-2 antibody response

Lin, Yi Chun; Cheng, Chien Yu; Chen, Cheng Pin; Cheng, Shu Hsing; Chang, Sui‐Yuan; Hsueh, Po-Ren

doi:10.1016/j.ijid.2020.05.070

Cited by 16 publications

(17 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because this woman had no known immunosuppressive disease and was not under immunosuppressive medication, transient SARS-CoV-2 existence without induction of a measurable antibody response is a plausible explanation for the negative test results. Similar observations have been reported in the recent literature [ 32 ]. Therefore, our study demonstrates the effect of individual variations in immunological responses to infection on the performance of serological tests.…”

Section: Discussionsupporting

confidence: 92%

“…To date, Taiwan has gone >100 days without reporting a single case of local transmission of COVID-19 [ 23 ]. Therefore, if a CLIA method (either Roche Test or Abbott Test) was applied for seroprevalence study for mass surveillance or among different risk populations in countries with a low prevalence of COVID-19 like Taiwan, further tests, including LFIAs, evaluation of the presence of anti-CMV antibodies or autoantibodies, the western blotting method, and even qRT-PCR assays for respiratory secretions of enrolled participants with positive results on CLIAs, are needed to confirm or exclude the presence of SARS-CoV-2 RNA or anti-SARS-CoV-2 antibodies [ 32 , 36 , 37 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan

Chen

Lee

Lin

et al. 2020

Emerging Microbes & Infections

Self Cite

View full text Add to dashboard Cite

This multicenter, retrospective study included 346 serum samples from 74 patients with coronavirus disease 2019 (COVID-19) and 194 serum samples from non-COVID-19 patients to evaluate the performance of five anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody tests, i.e. two chemiluminescence immunoassays (CLIAs): Roche Elecsys® Anti-SARS-CoV-2 Test (Roche Test) and Abbott SARS-CoV-2 IgG (Abbott Test), and three lateral flow immunoassays (LFIAs): Wondfo SARS-CoV-2 Antibody Test (Wondfo Test), ASK COVID-19 IgG/IgM Rapid Test (ASK Test), and Dynamiker 2019-nCoV IgG/IgM Rapid Test (Dynamiker Test). We found high diagnostic sensitivities (%, 95% confidence interval [CI]) for the Roche Test (97.4%, 93.4–99.0%), Abbott Test (94.0%, 89.1–96.8%), Wondfo Test (91.4%, 85.8–94.9%), ASK Test (97.4%, 93.4–99.0%), and Dynamiker Test (90.1%, 84.3–94.0%) after >21 days of symptom onset. Meanwhile, the diagnostic specificity was 99.0% (95% CI, 96.3–99.7%) for the Roche Test, 97.9% (95% CI, 94.8–99.2%) for the Abbott Test, and 100.0% (95% CI, 98.1–100.0%) for the three LFIAs. Cross-reactivity was observed in sera containing anti-cytomegalovirus (CMV) IgG/IgM antibodies and autoantibodies. No difference was observed in the time to seroconversion detection of the five serological tests. Specimens from patients with COVID-19 pneumonia demonstrated a shorter seroconversion time and higher chemiluminescent signal than those without pneumonia. Our data suggested that understanding the dynamic antibody response after COVID-19 infection and performance characteristics of different serological test are crucial for the appropriate interpretation of serological test result for the diagnosis and risk assessment of patient with COVID-19 infection.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan

Chen

Lee

Lin

et al. 2020

Emerging Microbes & Infections

Self Cite

View full text Add to dashboard Cite

show abstract

“…Regarding the protective immunity, Alonso, et al hypothesized the first mild viral infection might not strong enough to establish a detectable humoral response [ 65 ]. It was also possible for the absence of IgM and IgG antibodies, which were capable of connecting to the virus and preventing it from entering the host cell [ 66 ], in the acute and convalescent serum of the reinfected patients [ 67 ]. Although neutralizing antibodies and memory B and T cells again some common human coronaviruses (HCoV) such as HCoV-229E and HCoV-OC43 were also suggested to confer cross-immunity against SARS-CoV-2 [ 68 ], a report based on data on 150 patients showed that the presence of serum IgM and IgG was not significantly associated with a lower rate of disease recurrence (OR = 0.92, 95% CI = 0.27–3.16) [ 69 ].…”

Section: Discussionmentioning

confidence: 99%

Characteristics of COVID-19 Recurrence: A Systematic Review and Meta-Analysis

Hoang

2021

Annals of Global Health

View full text Add to dashboard Cite

Background: Previous studies reported the recurrence of coronavirus disease 2019 (COVID-19) among discharge patients. This study aimed to examine the characteristic of COVID-19 recurrence cases by performing a systematic review and meta-analysis. Methods: A systematic search was performed in PubMed and Embase and gray literature up to September 19, 2020. A random-effects model was applied to obtain the pooled prevalence of disease recurrence among recovered patients and the prevalence of subjects underlying comorbidity among recurrence cases. The other characteristics were calculated based on the summary data of individual studies. Results: A total of 41 studies were included in the final analysis, we have described the epidemiological characteristics of COVID-19 recurrence cases. Of 3,644 patients recovering from COVID-19 and being discharged, an estimate of 15% (95% CI, 12% to 19%) patients was re-positive with SARS-CoV-2 during the follow-up. This proportion was 14% (95% CI, 11% to 17%) for China and 31% (95% CI, 26% to 37%) for Korea. Among recurrence cases, it was estimated 39% (95% CI, 31% to 48%) subjects underlying at least one comorbidity. The estimates for times from disease onset to admission, from admission to discharge, and from discharge to RNA positive conversion were 4.8, 16.4, and 10.4 days, respectively. Conclusion: This study summarized up-to-date evidence from case reports, case series, and observational studies for the characteristic of COVID-19 recurrence cases after discharge. It is recommended to pay attention to follow-up patients after discharge, even if they have been in discharge quarantine.

show abstract

“…Our patient, on the other hand, presented a more potent form of COVID-19 after more than 40 days from the rst mild infection, and with a detectable antibody response only after the second infectious episode. Our hypothesis is that the rst mild infection was not su cient to build up a detectable humoral response [8], which occurred only after 14 days of a second more severe episode. In addition, the absence of detectable antibodies in the rst episode may have allowed for a new infection, rather than a recurrence.…”

Section: Discussionmentioning

confidence: 97%

“…On the other hand, a re-infection with a new or maybe the same circulating strain is not unfeasible [3], given the different pro les of immune response to the virus [7]. In fact, the detection of SARS-Cov-2 RNA with the absence of anti-SARS-CoV-2 antibody response has been previously observed [8].…”

Section: Discussionmentioning

confidence: 99%

Recurrence of COVID-19 with SARS-CoV-2 RNA reversion to positive and late antibody response: a case report from Brazil

Alonso

Sabino

Guimarães

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract In general, replication of the SARS-CoV-2 in the host reaches its peak in the first week of infection, decreasing rapidly afterwards, while some level of immunity is build up. Yet, the infection seems to follow a distinctive course in some individuals, reactivating after the apparent resolution of symptoms. We report here the first case of a more vigorous COVID-19 recurrence with SARS-CoV-2 RNA reversion to positive and late antibody response, and also the first to address COVID-19 recurrence in Brazil.

show abstract

A case of transient existence of SARS-CoV-2 RNA in the respiratory tract with the absence of anti-SARS-CoV-2 antibody response

Cited by 16 publications

References 9 publications

Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan

Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan

Characteristics of COVID-19 Recurrence: A Systematic Review and Meta-Analysis

Recurrence of COVID-19 with SARS-CoV-2 RNA reversion to positive and late antibody response: a case report from Brazil

Contact Info

Product

Resources

About